10 Einträge gefunden

1. Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey

   1. Lebwohl, Mark
   2. Langley, Richard G
   3. Paul, Carle
   4. Puíg, Lluis
   5. Reich, Kristian
   6. van de Kerkhof, Peter
   7. Wu, Hsiuan-Lin

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
2. Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4)

   1. Bieber, Thomas
   2. Reich, Kristian
   3. Paul, Carle
   4. Tsunemi, Yuichiro
   5. Augustin, Matthias
   6. Lacour, Jean-Philippe
   7. Ghislain, Pierre-Dominique

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
3. Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study

   1. Blauvelt, Andrew
   2. Armstrong, April W
   3. Langley, Richard G
   4. Gebauer, Kurt
   5. Thaçi, Diamant
   6. Bagel, Jerry
   7. Guenther, Lyn C

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
4. Unmet medical needs in the treatment of atopic dermatitis in infants: An Expert consensus on safety and efficacy of pimecrolimus

   1. Luger, Thomas
   2. Augustin, Matthias
   3. Lambert, Julien
   4. Paul, Carle
   5. Pincelli, Carlo
   6. Torrelo, Antonio
   7. Vestergaard, Christian

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
5. Bimekizumab versus Secukinumab in Plaque Psoriasis

   1. Reich, Kristian
   2. Warren, Richard B
   3. Lebwohl, Mark
   4. Gooderham, Melinda
   5. Strober, Bruce
   6. Langley, Richard G
   7. Paul, Carle

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
6. Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure

   1. Armstrong, April
   2. Paul, Carle
   3. Puig, Luis
   4. Boehncke, Wolf Henning
   5. Freeman, Michael
   6. Torii, Hideshi
   7. Papp, Kim

   2020 - Forschungsinformationssystem des UKE
7. Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL)

   1. Lacour, Jean-Philippe
   2. Bewley, Anthony
   3. Hammond, Edward
   4. Hansen, Jes B
   5. Horne, Laura
   6. Paul, Carle
   7. Reich, Kristian

   2020 - Forschungsinformationssystem des UKE
8. Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis

   1. Langley, Richard G B
   2. Reich, Kristian
   3. Strand, Vibeke
   4. Feldman, Steven R
   5. Paul, Carle
   6. Gordon, Kenneth
   7. Warren, Richard B

   2020 - Forschungsinformationssystem des UKE
9. Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: Results Through 48 Weeks of a Phase 3, Multicenter, Randomized, Double-Blinded, Etanercept- and Placebo-Controlled Study (CIMPACT)

   1. Lebwohl, Mark
   2. Blauvelt, Andrew
   3. Paul, Carle
   4. Sofen, Howard
   5. Węgłowska, Jolanta
   6. Piguet, Vincent
   7. Burge, Daniel

   2018 - Forschungsinformationssystem des UKE
10. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

    1. Griffiths, Christopher E M
    2. Reich, Kristian
    3. Lebwohl, Mark
    4. van de Kerkhof, Peter
    5. Paul, Carle
    6. Menter, Alan
    7. Cameron, Gregory S

    2015 - Forschungsinformationssystem des UKE